L
Lynn S. Ashby
Researcher at Barrow Neurological Institute
Publications - 59
Citations - 2593
Lynn S. Ashby is an academic researcher from Barrow Neurological Institute. The author has contributed to research in topics: Temozolomide & Oligodendroglial Tumor. The author has an hindex of 22, co-authored 57 publications receiving 2003 citations. Previous affiliations of Lynn S. Ashby include St. Joseph's Hospital and Medical Center & Saint Joseph's Hospital of Atlanta.
Papers
More filters
Journal ArticleDOI
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor,Paul Mulholland,Bart Neyns,L. Burt Nabors,Mario Campone,Antje Wick,Warren P. Mason,Tom Mikkelsen,Surasak Phuphanich,Lynn S. Ashby,John DeGroot,Rao Gattamaneni,Lawrence Cher,Mark Rosenthal,F. Payer,Juliane M. Jürgensmeier,Rakesh K. Jain,A. Gregory Sorensen,John Xu,Qi Liu,Martin J. van den Bent +20 more
TL;DR: This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomUSTine in patients with recurrent glioblastoma, although cedIRanib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.
Journal ArticleDOI
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
Mark E. Oppenlander,Andrew B. Wolf,Laura A. Snyder,Robert Bina,Jeffrey R. Wilson,Stephen W. Coons,Lynn S. Ashby,David Brachman,Peter Nakaji,Randall W. Porter,Kris A. Smith,Robert F. Spetzler,Nader Sanai +12 more
TL;DR: For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression.
Journal ArticleDOI
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors,Karen Fink,Tom Mikkelsen,Danica Grujicic,Rafal Tarnawski,Do-Hyun Nam,Maria Mazurkiewicz,Michael Salacz,Lynn S. Ashby,Vittorina Zagonel,Roberta Depenni,James Perry,Christine Hicking,Martin Picard,Monika E. Hegi,Benoit Lhermitte,David A. Reardon +16 more
TL;DR: Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RT→TMZ and a limited sample size did not allow firm conclusions regarding clinical efficacy in this exploratory phase II study.
Journal ArticleDOI
Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG 0539
Leland Rogers,Peixin Zhang,Michael A. Vogelbaum,Arie Perry,Lynn S. Ashby,Jignesh M. Modi,Anthony M. Alleman,James M. Galvin,David Brachman,Joseph M. Jenrette,John de Groot,Joseph Bovi,Maria Werner-Wasik,Jonathan P.S. Knisely,Minesh P. Mehta +14 more
TL;DR: The first clinical outcomes report from NRG Oncology RTOG 0539 supports the use of postoperative RT for newly diagnosed gross-totally resected WHO Grade II or recurrent WHO Grade I meningioma irrespective of resection extent and document minimal toxicity and high rates of tumor control with IMRT.
Journal ArticleDOI
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Andrew B. Lassman,Fabio M. Iwamoto,Fabio M. Iwamoto,Timothy F. Cloughesy,Kenneth Aldape,Andreana L. Rivera,April F. Eichler,David N. Louis,Nina Paleologos,Barbara Fisher,Lynn S. Ashby,J. Gregory Cairncross,Gloria Roldán,Patrick Y. Wen,Keith L. Ligon,David Schiff,H. Ian Robins,Brandon G. Rocque,Marc C. Chamberlain,Warren P. Mason,Susan A. Weaver,Richard M. Green,Francois G. Kamar,Lauren E. Abrey,Lisa M. DeAngelis,Suresh C. Jhanwar,Marc K. Rosenblum,Katherine S. Panageas +27 more
TL;DR: Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion, and PCV appeared to offer longer disease Control than temozolomide but without a clear survival advantage.